search
Back to results

Efficacy of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Children (5-<12 Years) With Acute Bronchial Obstruction

Primary Purpose

Acute Bronchial Obstruction, Asthma

Status
Completed
Phase
Phase 4
Locations
Venezuela
Study Type
Interventional
Intervention
Formoterol fumerate
fenoterol/ipratropium bromide
Sponsored by
Novartis
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Bronchial Obstruction, Asthma focused on measuring Asthma, Formoterol, Bronchial Obstruction, Children

Eligibility Criteria

5 Years - 12 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Asthmatic children 5-<12 years old, requiring emergency services for acute bronchial obstruction mild to moderate determined by functional and clinical evidence

Exclusion Criteria:

  • Patients with severe acute bronchial obstruction determined by functional and clinical evidence
  • Patients unable to use the inhaling device at time of treatment
  • Patients who received a bronchodilator drug within the last 12 hours
  • Patients who received inhaled steroids within the last 72 hours
  • Patients who received systemic steroids within the last 7 days
  • Patients with near fatal asthma history
  • Patients with fever (>38.5°C axillar temp)
  • Patients with any clinical significance condition

Other protocol-defined inclusion/exclusion criteria may apply

Sites / Locations

  • Novartis Investigator site - five sites in Caracas
  • Novartis Investigator Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Formoterol (Foradil®)

Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg

Arm Description

Formoterol (Foradil®) 12 micrograms administered through Aerolizer®.

Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg 20 drops in 3 mL of saline solution nebulized.

Outcomes

Primary Outcome Measures

Mean Change in Maximum Expiratory Flow From Baseline to Final Evaluation
Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Maximum Expiratory Flow.
Mean Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline to Final Evaluation
Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Forced Expiratory Volume in 1 second. FEV1 is defined as the volume of air that can be forced out of the lungs in 1 second after taking a deep breath.
Mean Change in Pulse Oxymetry From Baseline to Final Evaluation
Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Pulse Oximetry used to monitor the percentage of oxygen saturation of hemoglobin in the blood.
Mean Change in the Conway Clinical Scale Score From Baseline to Final Evaluation
Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by the Conway Clinical Scale. Assessment of the following: Wheezing, Accessory Muscle Use and Pulse Frequency in a 0 to 3 point scale according to severity for a minimum of 0 points and a total of 9 points in a very severe clinical case.

Secondary Outcome Measures

Safety Assessed by: Pulse Oxymetry, Clinical Assessments, Adverse Events
Not posted: see comment in Limitations and Caveats.
Pharmacoeconomic Analysis
Pharmacoeconomic analysis comparing the mean direct costs (total cost per prescription) of treatment with Formoterol (Foradil®) to treatment with Fenoterol 0.5 mg + Berodual®.

Full Information

First Posted
April 13, 2007
Last Updated
March 23, 2011
Sponsor
Novartis
search

1. Study Identification

Unique Protocol Identification Number
NCT00460577
Brief Title
Efficacy of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Children (5-<12 Years) With Acute Bronchial Obstruction
Official Title
Randomized, Double Blind, Double Dummy, Placebo Controlled Trial to Compare the Effectiveness of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Asthmatic Children (5-<12 Years) With Acute Bronchial Obstruction Attending Emergency Services
Study Type
Interventional

2. Study Status

Record Verification Date
March 2011
Overall Recruitment Status
Completed
Study Start Date
March 2007 (undefined)
Primary Completion Date
September 2008 (Actual)
Study Completion Date
September 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Novartis

4. Oversight

5. Study Description

Brief Summary
To determine efficacy and tolerability of inhaled Formoterol vs nebulized Ipatropioum Bromide plus Fenoterol in cumulative sequential doses in asthmatic children (5-<12 years) with acute bronchial obstruction attending emergency services

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Bronchial Obstruction, Asthma
Keywords
Asthma, Formoterol, Bronchial Obstruction, Children

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Formoterol (Foradil®)
Arm Type
Active Comparator
Arm Description
Formoterol (Foradil®) 12 micrograms administered through Aerolizer®.
Arm Title
Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg
Arm Type
Active Comparator
Arm Description
Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg 20 drops in 3 mL of saline solution nebulized.
Intervention Type
Drug
Intervention Name(s)
Formoterol fumerate
Intervention Description
12 micrograms stat (twice if necessary). Inhaled via aerolizer
Intervention Type
Drug
Intervention Name(s)
fenoterol/ipratropium bromide
Intervention Description
0.5 micrograms/0.25 milligrams (20 drops) inhaled via nebulization diluted in 3cc of 0.9% saline.
Primary Outcome Measure Information:
Title
Mean Change in Maximum Expiratory Flow From Baseline to Final Evaluation
Description
Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Maximum Expiratory Flow.
Time Frame
Baseline,4 hours
Title
Mean Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline to Final Evaluation
Description
Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Forced Expiratory Volume in 1 second. FEV1 is defined as the volume of air that can be forced out of the lungs in 1 second after taking a deep breath.
Time Frame
Baseline,4 hours
Title
Mean Change in Pulse Oxymetry From Baseline to Final Evaluation
Description
Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Pulse Oximetry used to monitor the percentage of oxygen saturation of hemoglobin in the blood.
Time Frame
Baseline, 4 hours
Title
Mean Change in the Conway Clinical Scale Score From Baseline to Final Evaluation
Description
Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by the Conway Clinical Scale. Assessment of the following: Wheezing, Accessory Muscle Use and Pulse Frequency in a 0 to 3 point scale according to severity for a minimum of 0 points and a total of 9 points in a very severe clinical case.
Time Frame
Baseline,4 hours
Secondary Outcome Measure Information:
Title
Safety Assessed by: Pulse Oxymetry, Clinical Assessments, Adverse Events
Description
Not posted: see comment in Limitations and Caveats.
Time Frame
4 hours
Title
Pharmacoeconomic Analysis
Description
Pharmacoeconomic analysis comparing the mean direct costs (total cost per prescription) of treatment with Formoterol (Foradil®) to treatment with Fenoterol 0.5 mg + Berodual®.
Time Frame
4 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Asthmatic children 5-<12 years old, requiring emergency services for acute bronchial obstruction mild to moderate determined by functional and clinical evidence Exclusion Criteria: Patients with severe acute bronchial obstruction determined by functional and clinical evidence Patients unable to use the inhaling device at time of treatment Patients who received a bronchodilator drug within the last 12 hours Patients who received inhaled steroids within the last 72 hours Patients who received systemic steroids within the last 7 days Patients with near fatal asthma history Patients with fever (>38.5°C axillar temp) Patients with any clinical significance condition Other protocol-defined inclusion/exclusion criteria may apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis de Venezuela
Organizational Affiliation
Novartis de Venezuela
Official's Role
Study Chair
Facility Information:
Facility Name
Novartis Investigator site - five sites in Caracas
City
Caracas
Country
Venezuela
Facility Name
Novartis Investigator Site
City
Maracaibo
Country
Venezuela

12. IPD Sharing Statement

Learn more about this trial

Efficacy of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Children (5-<12 Years) With Acute Bronchial Obstruction

We'll reach out to this number within 24 hrs